Drugs for Treating Chronic Obesity

Future Treatment for Insulin Resistance and Chronic Obesity

It was interesting to understand the differences in norepinephrine regarding when it is a hormone and a neurotransmitter. The differentiation allows one to see how it serves two purposes based on its release location. The information lays a good foundation for understanding the medications for treating insulin resistance and chronic obesity. Armed with knowledge on the drug process in the body will improve the development of drugs targeting insulin resistance as we will know how the drug interacts and its effects on the individual. These drugs have adverse side effects that result in most of them being withdrawn from the market. Some of the side effects include upset stomach, constipation, diarrhea, low blood sugar, dizziness, fatigue, and increased lipase (1). With these side effects, most people stop the drugs, which negates their efficacy. Moreover, the drugs have limited efficacies, making them ineffective in treating chronic obesity (2).

While insulin resistance and chronic obesity are vital areas for treatment, medications targeting these conditions have not been effective. The significant risk is denying people the opportunity to modify their lifestyles because they have medicines that can counter the effects of their destructive lifestyles. It is novel to develop medications for the treatment of chronic obesity. However, such drugs will lead to more lazy humans since the need for exercise is not mandatory, and one only needs to take a pill to cure their obesity. Fitness will become a thing of the past, and the need for fitness will be eliminated. The medications could lead to unhealthy bones since individuals will no longer exercise, resulting in lean unhealthy citizens. People should be educated on the benefits of leading healthy lives and reducing the consumption of junk foods. According to 1 Corinthians, 6:19-20, humans should glorify God in their bodies. Therefore, living unhealthy lifestyles demonstrates a failure to glorify God since God cannot live in a dirty, unhealthy body.

References

1. Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. Journal of hypertension 36: 1441-1455, 2018.